CALGARY,
AB, Sept. 8, 2022 /CNW/ - Zylorion Health
Inc., ("Zylorion" or the "Company"), a precision
mental health care and psychedelic therapy focused innovator, is
pleased to announce the addition of Mr. Jeroen Tas to the
Company's Board of Directors, and the addition of Dr. Ted Goldstein to the Company's Digital Health
Advisory Committee.
"We are extremely pleased to have Mr. Tas and Dr. Goldstein join
our Company. In addition to being recognized and celebrated as
leaders in transformative tech and innovation, Mr. Tas and Dr.
Goldstein have a track record of successful entrepreneurship and
bring very relevant and deep experience in healthcare, health
technologies, and bioinformatics", commented Dr. Peter Silverstone, Chief Executive Officer.
About Mr. Jeroen Tas
Mr. Tas previously served as Chief Innovation and Strategy
Officer with Koninklijke Philips N.V. ("Philips") (NYSE:
PHG) (AMS: PHIA), a leading global health technology company. Prior
to joining Philips, Mr. Tas co-founded and served
as President, COO and Vice Chairman of Mphasis Ltd., a global
technology solutions company. Mr. Tas also led Transaction
Technology Inc., Citi's tech lab, where he oversaw the first launch
of internet banking, new payment networks
and internet-based self-service devices.
Mr. Tas previously served as an observer to Zylorion's Board of
Directors and as a member of the Digital Health Advisory
Committee.
About Dr. Ted Goldstein
Dr. Goldstein most recently served as Chief Artificial
Intelligence Officer with Elevance Health Inc. (NYSE: ELV),
formerly Anthem Inc., where he oversaw the development of
'HealthOS', an artificial intelligence-based health operating
system. Dr. Goldstein was previously Vice President of Software
Tools at Apple (NASDAQ: AAPL), where he led the team that created
Xcode, Mac OS X, and iOS runtime operating systems for Mac and
iPhone. Before Apple, Dr. Goldstein served as Chief Java Commerce
Officer with Sun Microsystems, where he was co-creator of the Java
programming language and designed the Java card system used in
billions of smartcards.
"We are excited to welcome to Mr. Tas and Dr. Goldstein to our
Company and look forward to working closely with them, as well as
with the rest of our Directors and Advisors, towards achieving our
mission of delivering innovative and effective new therapies that
will enable those suffering from mental health challenges to
thrive", noted Dr. Silverstone.
About Zylorion
Zylorion is a biotech company engaged in the development and
delivery of integrated precision mental health therapies to address
psychological and neurological mental health conditions. Zylorion
is focused on the research, development and commercialization of
psychedelic-based compounds coupled with novel therapeutic
treatment programs targeting a continuum of mental health
conditions, such as MDD (major depressive disorder), TRD (treatment
resistant depression), PTSD (post-traumatic stress disorder),
general depression, anxiety disorders, and a number of addictive
tendencies. Zylorion aims to leverage leading technologies to
support the scalability and accessibility of its integrated therapy
programs in its mission to enable those experiencing mental health
challenges to thrive.
Cautionary Note Regarding
Forward-Looking Statements
This news release contains statements that constitute
forward-looking information ("forward-looking information") within
the meaning of the applicable Canadian securities legislation. All
statements, other than statements of historical fact, are
forward-looking information and are based on expectations,
estimates and projections as at the date of this news release. Any
statement that discusses predictions, expectations, beliefs, plans,
projections, objectives, assumptions, future events or performance
(often but not always using phrases such as "expects", or "does not
expect", "is expected", "anticipates" or "does not anticipate",
"plans", "budget", "scheduled", "forecasts", "estimates",
"believes" or "intends" or variations of such words and phrases or
stating that certain actions, events or results "may" or "could",
"would", "might" or "will" be taken to occur or be achieved) are
not statements of historical fact and may be forward-looking
information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zylorion-announces-additions-to-board-of-directors-and-advisory-committee-301620063.html
SOURCE Zylorion